Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Period	TotalRevenue
2015-12-31	$19.96B
2016-12-31	$21.22B
2017-12-31	$22.87B
2018-12-31	$21.49B
2019-12-31	$22.32B
2020-12-31	$24.54B
2021-12-31	$28.32B
2022-12-31	$28.54B
2023-12-31	$34.12B
2024-12-31	$45.04B

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LLY	$935.58	+0.00%	2.73M
3
4
5

Eli Lilly and Company (LLY) Revenue History

Revenue Data

Get Eli Lilly and Company Data in Excel

More LLY Financial Data